flu like symptoms; Fever; Chills; sweating profusely; Ache; This is a spontaneous report from a contactable Healthcare Professional. A healthy female patient of an unspecified age received the first dose of BNT162B2 Pfizer-BioNTech COVID-19 mRNA Vaccine via an unspecified route of administration, in left arm on 02Feb2021 at 12:30PM (Batch/Lot Number: EL9261; Expiration Date: Jul2021) as single dose for COVID-19 immunization. Medical history included anaemia: she has been anemic for at least 3 years, she said she knows anemia is considered to be a blood disorder, but she feels her anemia is very common; she said her anemia is related to a fibroid that causes heavy menstrual bleeding. The patient reported that her husband was COVID-19 positive in late Oct2020. She initially tested negative, but felt ill while quarantined with her husband and was never retested to see if she was positive. She believes she was. She said she and her husband quarantined together at home for 14 days, and their quarantine ended a week before Thanksgiving (2020.) She said she believes she got the COVID-19 Virus a week or two after her husband tested positive for the COVID-19 Virus because she had symptoms during that time. She said since she was already quarantining at home, she did not go and have a second COVID-19 Virus test. She reported that when she had symptoms while she was quarantining in late Oct2020 and Nov2020, she drank ginger tea, saying ginger tea has anti-inflammatory properties. There were no concomitant medications. On 02Feb2021 at around 8:00PM-9:00PM the patient experienced flu like symptoms, fever, chills, sweating profusely and ache, which lasted for the first 24 hours and then resolved, but didn't lose her sense of taste or smell. She clarified she felt like she had a fever, but never checked her temperature because her thermometer was not working at the time. She said she thought she had a fever because she had chills, was sweating profusely, and was achy the night of 02Feb2021. She took 2 Ibuprofen 200 mg tablets (400 mg total), Lot Number: 9KE2695A, Expiration Date: Jul2021, the next day, on 03Feb2021. Moreover, she said that, when she didn't feel good after having her first COVID-19 Vaccine dose, she had a cup of ginger tea later on in the day of 03Feb2021 (approximately 4:00 PM). She said she makes the ginger tea herself with fresh ginger and lemon in warm water. She is scheduled to receive dose two of the vaccine on 23Feb2021. She has heard that the second dose of the vaccine has made people ill and is thinking the antibodies that she has from having COVID-19 in Oct2020 caused her to have the flu like symptoms she experienced after the first dose of the vaccine. She said she is nervous about getting her second COVID-19 Vaccine shot because she has heard people are sick for 3-4 days after getting the second COVID-19 Vaccine shot. She said her husband already had tested for the COVID-19 Virus antibodies. She asked if she already had the COVID-19 Virus antibodies, would the first COVID-19 Vaccine shot be doing what the second COVID-19 Vaccine shot was doing for everybody else. The patient clarified she was never tested for the COVID-19 Virus antibodies. The patient underwent lab tests and procedures which included complete full blood count on and unknown date and SARS-CoV-2 antibody test: negative in Oct2020. She explained she gets her iron levels checked 3 times a year and has a CBC done to monitor her anemia. The reported events resolved on 03Feb2021.  As of 21Jan2020, a search of the published medical literature identified limited information regarding the use of Pfizer-BioNTech COVID-19 Vaccine (also known as BNT162b2) in patients with COVID-19 or tested positive for COVID 19. A summary of relevant information follows. Data from clinical trials indicate that mRNA COVID-19 vaccines can safely be given to persons with evidence of a prior SARS-CoV-2 infection. Vaccination should be offered to persons regardless of history of prior symptomatic or asymptomatic SARS-CoV-2 infection. Viral testing to assess for acute SARS-CoV-2 infection or serologic testing to assess for prior infection for the purposes of vaccine decision-making is not recommended. Vaccination of persons with known current SARS-CoV-2 infection should be deferred until the person has recovered from the acute illness (if the person had symptoms) and criteria have been met for them to discontinue isolation. This recommendation applies to persons who develop SARS-CoV-2 infection before receiving any vaccine doses as well as those who develop SARS-CoV-2 infection after the first dose but before receipt of the second dose. While there is no recommended minimum interval between infection and vaccination, current evidence suggests that the risk of SARS-CoV-2 reinfection is low in the months after initial infection but may increase with time due to waning immunity. Thus, while vaccine supply remains limited, persons with recent documented acute SARS-CoV-2 infection may choose to temporarily delay vaccination, if desired, recognizing that the risk of reinfection, and therefore the need for vaccination, may increase with time following initial infection. For vaccinated persons who subsequently develop COVID-19, prior receipt of an mRNA COVID-19 vaccine should not affect treatment decisions (including use of monoclonal antibodies, convalescent plasma, antiviral treatment, or corticosteroid administration) or timing of such treatments.  No follow-up attempts are possible. No further information is expected.